Position in GALT
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$0
New position
Shares Held
0
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Derivatives in GALT
reported options exposure · as of Mar 31, 2026CallValue
$2,232,000
CallShares
800,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026GREAT POINT PARTNERS LLC holds $375,251,240 across 36 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
374,000 | $31,479,580 | |
| 2 | VOR |
Vor Biopharma Inc.
|
1,750,000 | $31,220,000 | |
| 3 | ZURA |
Zura Bio Ltd
|
4,215,930 | $25,084,783 | |
| 4 | NKTR |
Nektar Therapeutics
|
316,453 | $22,768,793 | |
| 5 | SLGL |
Sol-Gel Technologies Ltd.
|
274,363 | $21,735,036 | |
| 6 | ALMS |
Alumis Inc.
|
856,061 | $18,859,023 | |
| 7 | DRUG |
Bright Minds Biosciences Inc.
|
220,000 | $16,053,400 | |
| 8 | ANNX |
Annexon, Inc.
|
2,500,000 | $13,850,000 |
All Filings in GALT
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,232,000 | 800,000 | Call | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||